Bernadette Chadefaux-Vekemans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bernadette Chadefaux-Vekemans has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chris Ottolenghi
Laboratory of Genetics, NIA/NIH-IRP, Baltimore, USA
1 shared publication - Daniel Ricquier
Service de Biochimie Métabolique, Tour Lavoisier étage 4, Hôpital Necker-Enfants Malades
1 shared publication - Georges Deschênes
Service de néphrologie pédiatrique, Hôpital Robert Debré, AP-HP, Paris, France
1 shared publication - Jean-Marc Tréluyer
Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin-Saint-Vincent-de-Paul, France
1 shared publication - Naïm Bouazza
EA 7323, Université Paris Descartes Sorbonne Paris Cité, Paris, France.
1 shared publication - Patrick Niaudet
Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 86
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific treatment for nephropathic cystinosis is cysteamine bitartrate. This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis.
- 1 January 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 86
Open AccessPopulation pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific treatment for nephropathic cystinosis is cysteamine bitartrate. This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis.